We developed an enzyme immunoassay (EIA) system to detect antibodies to human T-lymphotropic virus type I (HTLV-I). This system uses chemically synthesized ohgopeptides to capture anti-HTLV-I antibodies In serum.
(PA) test involving gelatin particlessensitized by viral proteins, and an indirect-immunofluorescence (IF) assay with an established T-cell line carrying HTLV-I. Although the PA test is the most-used diagnostic method for this in Japan, this test often gives false-positive results because of cellmembrane proteins associated with virus particles, and positive results must therefore be confirmed by other methods (10, 11).
On the other hand, Western blot and IF methods are more reliable than PA and can be used for confirming seropositivity. A we added two lysine residues to the amino-terminal of each peptide to improve binding to the surface of the wells. The N-terminal (Lys-Lys)-peptide-based EIA showed greater sensitivity than either a C-terminal (Lys-Lys)-peptidebased EIA or a nonmodifled peptide-based EIA (data not shown). We assume that the positive charges provided by the lysine residues interact more strongly with the surface of the wells and thereby allow other parts of the peptide to interact more freely with antibody. Here we describe the results of mass screening of HTLV-I carriers by EIA involving a mixture of these two synthetic oligopeptides (SP-EIA).
Material and Methods

Specimens
Serum specimens from 21894 healthy donors were obtained from the Fukuoka Red Cross Blood Center from April 1990 to May 1990. These specimens were examined for anti-HTLV-I antibodies by two PA tests (Serodia-ATLA and Serodia-HTLV-I; Fjirebio Inc., Tokyo, Japan) and an IF assay. Serodia-HTLV-I is a new PA test improved by sensitizing the surface of gelatin particles with viral protein enriched with envelope protein. In the IF assay, acetone-fixed MT-2 cells were used as antigens according to the standard criteria of the Japan Red Cross.
Peptide Synthesis
Peptides were synthesized on the basis of the amino acid sequence deduced from the nucleotide sequence of HTLV-I (5). Hydrophilicity/hydrophobicity and secondary structure of HTLV-I viral proteins encoded by gag, pol, enu, and pX genes were analyzed by software for processing genetic information (sDc-GENrYx; Software Development Co., Ltd., Tokyo, Japan) (20 and incubated the samples for 15 miii at room temperature. We stopped the reaction by adding 100 L of 1 mol/L H2S04 to each well. Absorbance was measured with a plate reader (Model MPR-A4; Tosoh Co., Ltd.) at 492 nm. The cutoff value for SP-EIA was calculated on the basis of data from 1116 PA-negative specimens as follows: cutoff value of 0.265 = mean (0.070) + 3 SDs (SD 0.065).
Inhibition Assay
We performed the inhibition test by pre-incubating the serum specimen with a 20-fold volume of 10 mmol/L PBS (pH 7.2) containing, per liter, 5 mg of peptides, 100 mL of normal goat serum, 0.5 mL of Tween 20, and 1 g of thimerosal for 60 miii at 37#{176}C. The procedure after pre-uncubation was as described above for SP-EIA. The inhibition ratio in the inhibition test was calculated as (A4 of SP-EIA -A of inhibition test)I(A4 of SP-EIA) x 100. The cutoff value for the inhibition test was set at 30% of the inhibition ratio.
IF procedure. The IF method was described previously (22) . Briefly, a cell suspension from an HTL V-I-positive cell line was dried on a microscope slide and fixed with acetone. The test sample was incubated with the fixed cells and then with fluorescein isothiocyanate-conjugated anti-human immunoglobulins.
After the second incubation, the slide was dried and examined by fluorescence microscopy. A positive reaction was detected by immunofluorescence.
PA procedure. We used either the Serodia-ATLA or the Serodia-HTLV-I kit. These assays use gelatin particles sensitized with HTLV-I-associated antigen, and a positive reaction is detected by the agglutination of the particles on exposure to antibody. The Serodia-ATLA kit uses antigen derived from a purified HTLV-I-carrying cell line, MT-2, whereas the Serodia-HTLV-I kit uses a combination of purified HTL V-I-associated antigen plus recombinant em' protein.
The 2 dilution factor of a sample is the highest serum dilution giving a positive agglutination reaction. A sample for which ii 4 is positive.
Results
We obtained 554 positive serum samples from an initial screen of 21894 blood donors, using the Serodia-ATLA and Serodia-HTLV-I PA kits. We reexamined these 554 positive samples, along with 1116 randomly selected negative samples, by the PA, IF, and SP-EIA detection methods. These results are summarized in Table 1 . In contrast, when specimens were examined by SP-EIA, 384 samples were positive, 3 of which were IF negative. We further examined the profiles of these three EIA-positive, IF-negative specimens, designating these as being from donors nos. 1, 2, and 3. Table 2 shows the results of the PA, IF, SP-EIA, and inhibition assays involving solutions of either mixed or individual gag p19 100-130 and em' gp46 175-199 peptides. Donor no. 1 was positive by both PA and SP-ELA but negative by IF. Binding of serum antibodies to the immobilized synthetic peptides in the SP-EIA method was inhibited by free competitor peptide (high inhibition ratio), indicating that this reaction was specific. Donor no. 1 was also positive by both Western blot and polymerase chain reaction (PCR) analyses (not shown). Donor no. 2 was negative by both PA and IF but positive by SP-EIA. However, with the SP-EIA we observed little inhibition (11.4%) when a mixture of the synthetic peptides was used as free competitor, suggesting that this SP-EIA reaction may be nonspecific. Donor no. 3 was negative by both PA and IF but positive by SP-EIA. This latter result was shown to be specific by the relatively great inhibition (96.3%) obtained by the SP-EIA with gp46. Donors nos. 2 and 3 were negative by Western blot and PCR analyses (data not shown). Figure 1 replots some of the data from Table 1 specimen in the 11 = 5 column. The correlation between samples that were undetectable by the PA assay below a dilution of 2 (i.e., n = 4 and n <4) was very good; 97.7% (42/43) of the samples within the n = 4 dilution group were also negative by IF and SP-ELA. As a whole, 63 of 108 specimens (58.3%) detectable by the PA assay at dilutions of 2 were negative by IF and SP-EIA. Thus, samples that tested positive bythe PA assay at these concentrations were considered to be false positives.
Discussion
Recently several successful attempts to use oligopeptides as antigemc agents in EIA for human immunodeficiency virus or hepatitis C virus were reported (23,24). Generally, 5-10 amino acid residues are believed to be needed for recognition by immunoglobulin antibodies (25) (26) (27) . The fact that EIAs with oligopeptides show high specificity and sensitivity indirectly supports this hypothesis (18,23,24) .
For practical purposes, both falsepositive and false-negative results must be minimized for accurate determinations of seropositivity. The SP-EIA test described here achieves increased accuracy by using a mixture of synthetic peptides as the immobilized antigen and by modifring these peptides by adding a Lys-Lys link to the native sequences (data not shown).
As shown in Table 1 specimens were negative by the more accurate IF assay. In contrast, of the 384 specimens that were positive by SP-EIA, only 3 were negative by IF. Moreover, of these three specimens, only one (donor no.2, Table 2 ) was found to be falsely positive by Western blot and PCR analyses. Thus, the SP-EIA assay proved more accurate than the IF assay, producing only 1 false positive out of 1670 specimens.
This conclusion is further illustrated in Figure 1 . We found that, whereas PA was unreliable in determining seropositivity in 2'-fold-diluted specimens with n <6, there was great agreement between the results obtained Our assay reduces the number of false-negative results obtained by EIA by using a mixture of synthetic peptides corresponding to regions gag p19 100-130 and enu gp46 175-199. In addition, we increased the specificity of this assay and, thus, decreased the frequency of false determinations by using peptides modified by adding Lys-Lys residues (data not shown). This reliable and sensitive method for detecting anti-HTLV-I antibodies in serum could be valuable for preventing HTLV-I transmission by transfusion, by mother's milk, or by sexual contact. We expect that this assay could prove useful not only as an alternative to IF in confirming seropositivity, but also as an alternative to PA in large-scale screenings for HTLV-I.
